NASDAQ:UPB Upstream Bio (UPB) Stock Price, News & Analysis $8.79 -0.57 (-6.09%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$8.80 +0.01 (+0.06%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Upstream Bio Stock (NASDAQ:UPB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Upstream Bio alerts:Sign Up Key Stats Today's Range$8.51▼$9.5250-Day Range$7.66▼$10.4952-Week Range$7.25▼$33.68Volume568,770 shsAverage Volume519,213 shsMarket Capitalization$478.35 millionP/E RatioN/ADividend YieldN/APrice Target$38.75Consensus RatingHold Company Overview Upstream Bio, Inc. is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges. The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages. In the immuno-oncology sphere, Upstream Bio is exploring therapeutic vaccine constructs designed to activate tumor-specific T cells, while its infectious disease programs seek to induce protective immunity against viral pathogens. By integrating translational biomarkers and adaptive clinical trial designs, the company strives to accelerate candidate selection and optimize dosing regimens. Upstream Bio operates research facilities in the United States and collaborates with academic and industry partners across several regions to advance its programs globally. The company’s leadership team comprises seasoned executives and scientists with deep expertise in virology, vaccine development and regulatory affairs. Upstream Bio is listed on the Nasdaq Global Market under the symbol UPB and continues to build strategic alliances aimed at expanding its pipeline and commercial capabilities.AI Generated. May Contain Errors. Read More Upstream Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreUPB MarketRank™: Upstream Bio scored higher than 48% of companies evaluated by MarketBeat, and ranked 576th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingUpstream Bio has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialUpstream Bio has a consensus price target of $38.75, representing about 340.8% upside from its current price of $8.79.Amount of Analyst CoverageUpstream Bio has only been the subject of 3 research reports in the past 90 days.Read more about Upstream Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Upstream Bio are expected to decrease in the coming year, from ($3.06) to ($3.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Upstream Bio is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Upstream Bio is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUpstream Bio has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.85% of the float of Upstream Bio has been sold short.Short Interest Ratio / Days to CoverUpstream Bio has a short interest ratio ("days to cover") of 5.71.Change versus previous monthShort interest in Upstream Bio has recently increased by 6.64%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUpstream Bio does not currently pay a dividend.Dividend GrowthUpstream Bio does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.31 News SentimentUpstream Bio has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Upstream Bio this week, compared to 3 articles on an average week.Search Interest2 people have searched for UPB on MarketBeat in the last 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Upstream Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,915.00 in company stock.Percentage Held by Insiders13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsUpstream Bio has minimal institutional ownership at this time.Read more about Upstream Bio's insider trading history. Receive UPB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UPB Stock News HeadlinesUpstream Bio (NASDAQ:UPB) Price Target Lowered to $50.00 at Mizuho1 hour ago | americanbankingnews.comUpstream Bio Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 13 at 7:00 AM | globenewswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today. | Profits Run (Ad)Upstream Bio stellt neue Daten zu Verekitug auf Fachkonferenz vorApril 17, 2026 | de.investing.comUpstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International ConferenceApril 17, 2026 | globenewswire.comUpstream Bio (UPB) price target decreased by 10.31% to 44.37April 10, 2026 | msn.comValidating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–RewardApril 7, 2026 | tipranks.comTruist senkt Kursziel für Upstream Bio wegen verzögertem StudienzeitplanApril 2, 2026 | de.investing.comSee More Headlines UPB Stock Analysis - Frequently Asked Questions How have UPB shares performed this year? Upstream Bio's stock was trading at $27.15 on January 1st, 2026. Since then, UPB shares have decreased by 67.6% and is now trading at $8.79. How were Upstream Bio's earnings last quarter? Upstream Bio, Inc. (NASDAQ:UPB) issued its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by $0.02. The business earned $1.03 million during the quarter, compared to the consensus estimate of $1.03 million. Upstream Bio had a negative net margin of 4,718.96% and a negative trailing twelve-month return on equity of 41.73%. When did Upstream Bio IPO? Upstream Bio (UPB) raised $200 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO. Who are Upstream Bio's major shareholders? Top institutional shareholders of Upstream Bio include Decheng Capital LLC (5.01%), Y Intercept Hong Kong Ltd (1.84%), SEB Asset Management AB (1.61%) and Pictet Asset Management Holding SA (1.35%). Insiders that own company stock include Erez Chimovits, Ai Upstream Llc and Michael Gray. View institutional ownership trends. How do I buy shares of Upstream Bio? Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/13/2026Today5/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 UPB's financial health is in the Red zone, according to TradeSmith. UPB has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UPB Previous SymbolNASDAQ:UPB CIK2022626 Webupstreambio.com Phone(781) 208-2466FaxN/AEmployees38Year Founded2021Price Target and Rating Average Price Target for Upstream Bio$38.75 High Price Target$50.00 Low Price Target$15.00 Potential Upside/Downside+340.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$143.44 million Net Margins-4,718.96% Pretax Margin-5,026.03% Return on Equity-41.73% Return on Assets-40.35% Debt Debt-to-Equity RatioN/A Current Ratio26.15 Quick Ratio26.15 Sales & Book Value Annual Sales$2.85 million Price / Sales167.84 Cash FlowN/A Price / Cash FlowN/A Book Value$6.29 per share Price / Book1.40Miscellaneous Outstanding Shares54,420,000Free Float47,041,000Market Cap$478.35 million OptionableN/A Beta1.28 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:UPB) was last updated on 5/15/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
